Merit Medical Systems Inc

  • Earnings Score
  • Moat Score
  • Safety Score
  • Market Cap $6.07B
  • PE 51
  • Debt $770.50M
  • Cash $525.28M
  • EV $6.31B
  • FCF $175.50M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings$120.04M
EBIT$152.74M
ROE9%
ROA6%
FCF$175.50M
Equity$1.32B
Growth Stability-39%
PE50.54
PEG0.56
PB4.58
P/FCF34.57
P/S4.58
Price/Cash0.09
Debt/Equity0.58
Debt/FCF4.39
Net Margins9%
Gross Margins47%
Op. Margins12%
Earnings CAGR14%
Sales Growth YoY8%
Sales Growth QoQ1%
Sales CAGR10%
FCF CAGR37%
Equity CAGR12%
Earnings Stability0.3
Earnings Growth YoY10%
Earnings Growth QoQ-20%
Earnings CAGR 5Y90%
Sales CAGR 5Y7%
FCF CAGR 5Y17%
Equity CAGR 5Y8%
Earnings CAGR 3Y8%
Sales CAGR 3Y8%
FCF CAGR 3Y21%
Equity CAGR 3Y9%
Market Cap$6.07B
Revenue$1.33B
Assets$2.38B
Total Debt$770.50M
Cash$525.28M
Shares Outstanding58.11M
EV6.31B
Earnings Score18%
Moat Score85%
Safety Score56%
Final Score53%
Working Capital877.24M
Current Ratio5.36
Gross Profit$620.88M
Shares Growth 3y1%
Equity Growth QoQ3%
Equity Growth YoY8%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for use in interventional cardiology, radiology, and endoscopy procedures. The firm reports through two units, Cardiovascular and Endoscopy. Cardiovascular consists of cardiology and radiology devices, which assist in diagnosing and treating coronary arterial disease, peripheral vascular disease, and other non-vascular diseases and include embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, breast cancer localization and guidance, biopsy, interventional oncology, and spine devices. Endoscopy segment consists of gastroenterology and pulmonology devices that assist in the palliative treatment of expanding esophageal, and biliary strictures caused by malignant tumors.

SEC Filings

Direct access to Merit Medical Systems Inc (MMSI) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Merit Medical Systems Inc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Merit Medical Systems Inc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 14%
Stability 30%
loading chart...

Merit Medical Systems Inc Discounted Cash Flow

Fully customizable DCF calculator online for Merit Medical Systems Inc.

= $23B
012345678910TV
fcf$175M$241M$330M$452M$620M$850M$1.2B$1.6B$2.2B$3B$4.1B$41B
DCF$219M$273M$340M$424M$528M$658M$820M$1B$1.3B$1.6B$16B
Value$23B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Net Margins5%4%3%4%5%1%-1%5%6%8%9%
ROA-5%4%4%4%1%-0%4%5%5%6%
ROE-5%4%4%5%1%-1%5%7%8%9%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Debt over FCF-11.7616.1412.3817.99-1.24K3.012.113.027.644.39
Debt over Equity0.540.470.670.440.450.470.370.240.180.70.58
Growth Stability---100%100%18%-39%100%100%100%-39%

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023CAGR 5Y
Revenue YoY growth-6%11%21%21%13%-3%12%7%9%7%
Earnings YoY growth-4%-15%37%53%-87%-281%-592%54%27%90%
Equity YoY growth-7%7%36%38%2%1%8%10%5%8%
FCF YoY growth--3%12%16%-4%-102%-33K%0%-42%60%17%